Ma, ChangshengChangshengMaJIUNN-LEE LINBai, RongRongBaiSun, YihongYihongSunNam, Gi-ByoungGi-ByoungNamStewart, JohnJohnStewartWieloch, MattiasMattiasWielochZhu, JunJunZhu2023-09-072023-09-072022-0901492918https://www.scopus.com/record/display.uri?eid=2-s2.0-85135353695&doi=10.1016%2fj.clinthera.2022.07.005&origin=inward&txGid=421289c60f67644e494d5034feb686fehttps://scholars.lib.ntu.edu.tw/handle/123456789/635156Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL). This post hoc analysis evaluated the efficacy and safety of dronedarone compared with placebo in populations from Asian and non-Asian regions randomized in the ATHENA trial (A Placebo-Controlled, Double-blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of CV Hospitalization or Death From Any Cause in Patients With AF/AFL).enAnti-arrhythmic drug; Asia; atrial fibrillation; cardiovascular disease; dronedarone[SDGs]SDG3journal article10.1016/j.clinthera.2022.07.005359270942-s2.0-85135353695